The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Acute graft versus host disease
Open accessAbstract
Acute graft-versus-host disease (GVHD) occurs after allogeneic hematopoietic stem cell transplant and is a reaction of donor immune cells against host tissues. Activated donor T cells damage host epithelial cells after an inflammatory cascade that begins with the preparative regimen. About 35%-50% of hematopoietic stem cell transplant (HSCT) recipients will develop acute GVHD. The exact risk is dependent on the stem cell source, age of the patient, conditioning, and GVHD prophylaxis used. Given the number of transplants performed, we can expect about 5500 patients/year to develop acute GVHD. Patients can have involvement of three organs: skin (rash/dermatitis), liver (hepatitis/jaundice), and gastrointestinal tract (abdominal pain/diarrhea). One or more organs may be involved. GVHD is a clinical diagnosis that may be supported with appropriate biopsies. The reason to pursue a tissue biopsy is to help differentiate from other diagnoses which may mimic GVHD, such as viral infection (hepatitis, colitis) or drug reaction (causing skin rash). Acute GVHD is staged and graded (grade 0-IV) by the number and extent of organ involvement. Patients with grade III/IV acute GVHD tend to have a poor outcome. Generally the patient is treated by optimizing their immunosuppression and adding methylprednisolone. About 50% of patients will have a solid response to methylprednisolone. If patients progress after 3 days or are not improved after 7 days, they will get salvage (second-line) immunosuppressive therapy for which there is currently no standard-of-care. Well-organized clinical trials are imperative to better define second-line therapies for this disease. Additional management issues are attention to wound infections in skin GVHD and fluid/nutrition management in gastrointestinal GVHD. About 50% of patients with acute GVHD will eventually have manifestations of chronic GVHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A., & Coffman, R. L. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.7.2348 · Cited by 7,506
1994 Consensus Conference on Acute GVHD Grading.
Przepiorka, D., Weisdorf, D., Martin, P., Hg, K., Beatty, P., Hows, J., & Thomas, E. D. (1995) · PubMed · Cited by 5,037
Szer, J. (1999) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,353
Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., et al. (1998) · Blood · doi:10.1182/blood.v91.3.756 · Cited by 2,071
Storb, R., Deeg, H. J., Whitehead, J., Appelbaum, F., Beatty, P., Bensinger, W., Buckner, C. D., Clift, R., Doney, K., Farewell, V., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603203141201 · Cited by 1,411
Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease
Ringdén, O., Uzunel, M., Rasmusson, I., Remberger, M., Sundberg, B., Lönnies, H., Marschall, H.-U., Dlugosz, A., Szakos, A., Hassan, Z., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000214462.63943.14 · Cited by 1,142
Kernan, N. A., Bartsch, G., Ash, R. C., Beatty, P. G., Champlin, R., Filipovich, A., Gajewski, J., Hansen, J. A., Henslee-Downey, J., McCullough, J., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303043280901 · Cited by 825
Marrow Transplantation from Related Donors Other Than HLA-Identical Siblings
Beatty, P. G., Clift, R. A., Mickelson, E. M., Nisperos, B. B., Flournoy, N., Martin, P. J., Sanders, J. E., Stewart, P., Buckner, C. D., Storb, R., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198509263131301 · Cited by 816
Hill, G. R., & Ferrara, J. L. M. (2000) · Blood · doi:10.1182/blood.v95.9.2754.009k25_2754_2759 · Cited by 715
Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 636
Nash, R. A., Antin, J. H., Karanes, C., Fay, J. W., Avalos, B. R., Yeager, A. M., Przepiorka, D., Davies, S. M., Petersen, F. B., Bartels, P., et al. (2000) · PubMed · Cited by 589
Clift, R., Buckner, C., Appelbaum, F., Bearman, S., Petersen, F., Fisher, L., Anasetti, C., Beatty, P., Bensinger, W., & Doney, K. (1990) · Blood · doi:10.1182/blood.v76.9.1867.1867 · Cited by 585
Szydlo, R., Goldman, J. M., Klein, J. P., Gale, R. P., Ash, R. C., Bach, F. H., Bradley, B. A., Casper, J. T., Flomenberg, N., Gajewski, J. L., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1767 · Cited by 468
Cutler, C., Giri, S., Jeyapalan, S., Paniagua, D., Viswanathan, A., & Antin, J. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3685 · Cited by 432
Flowers, M. E. D., Parker, P. M., Johnston, L. J., Matos, A. V. B., Storer, B., Bensinger, W. I., Storb, R., Appelbaum, F. R., Forman, S. J., Blume, K. G., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0011 · Cited by 421
How I treat refractory acute GVHD
Deeg, H. J. (2007) · Blood · doi:10.1182/blood-2006-12-041889 · Cited by 407
Pathophysiologic mechanisms of acute graft-vs.-host disease
Ferrara, J. L. M., Levy, R., & Chao, N. J. (1999) · Biology of Blood and Marrow Transplantation · doi:10.1016/s1083-8791(99)70011-x · Cited by 340
WEISDORF, D., HAKKE, R., BLAZAR, B., MILLER, W., MCGLAVE, P., RAMSAY, N., KERSEY, J., & FILIPOVICH, A. (1991) · Transplantation · doi:10.1097/00007890-199106000-00010 · Cited by 278
Yakoub-Agha, I., Mesnil, F., Kuentz, M., Boiron, J. M., Ifrah, N., Milpied, N., Chehata, S., Esperou, H., Vernant, J.-P., Michallet, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0952 · Cited by 268
Tumor necrosis factor-α blockade for the treatment of acute GVHD
Couriel, D., Saliba, R., Hicks, K., Ippoliti, C., de Lima, M., Hosing, C., Khouri, I., Andersson, B., Gajewski, J., Donato, M., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4241 · Cited by 261
Pérez-Simón, J. A., Kottaridis, P. D., Martino, R., Craddock, C., Caballero, D., Chopra, R., Garcı́a-Conde, J., Milligan, D. W., Schey, S., Urbano-Ispizua, A., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0701 · Cited by 245
The Pathophysiology of Acute Graft-versus-Host Disease
Ferrara, J. L. M., Cooke, K. R., & Teshima, T. (2003) · International Journal of Hematology · doi:10.1007/bf02983793 · Cited by 235
Cahn, J.-Y. (2005) · Blood · doi:10.1182/blood-2004-11-4557 · Cited by 221
Champlin, R., Ho, W., Gajewski, J., Feig, S., Burnison, M., Holley, G., Greenberg, P., Lee, K., Schmid, I., & Giorgi, J. (1990) · Blood · doi:10.1182/blood.v76.2.418.418 · Cited by 191
Marty, F. M., Lee, S. J., Fahey, M. M., Alyea, E. P., Soiffer, R. J., Antin, J. H., & Baden, L. R. (2003) · Blood · doi:10.1182/blood-2003-01-0267 · Cited by 190
SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1
Benito, A. I., Furlong, T., Martin, P. J., Anasetti, C., Appelbaum, F. R., Doney, K., Nash, R. A., Papayannopoulou, T., Storb, R., Sullivan, K. M., et al. (2001) · Transplantation · doi:10.1097/00007890-200112270-00010 · Cited by 184
Schmaltz, C., Alpdogan, O., Horndasch, K. J., Muriglan, S. J., Kappel, B. J., Teshima, T., Ferrara, J. L. M., Burakoff, S. J., & van den Brink, M. R. M. (2001) · Blood · doi:10.1182/blood.v97.9.2886 · Cited by 181
Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A., & Coffman, R. L. (2005) · The Journal of Immunology · doi:10.1093/jimmunol/175.1.5 · Cited by 161
Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment
Arai, S., Margolis, J., Zahurak, M., Anders, V., & Vogelsang, G. B. (2002) · Biology of Blood and Marrow Transplantation · doi:10.1053/bbmt.2002.v8.pm11939605 · Cited by 159
Self-citationMartin, P. J., McDonald, G. B., Sanders, J. E., Anasetti, C., Appelbaum, F. R., Deeg, H. J., Nash, R. A., Petersdorf, E. W., Hansen, J. A., & Storb, R. F. (2004) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2003.12.304 · Cited by 157
Petersdorf, E. W., Kollman, C., Hurley, C. K., Dupont, B., Nademanee, A. P., Begovich, A. B., Weisdorf, D. J., & McGlave, P. B. (2001) · Blood · doi:10.1182/blood.v98.10.2922 · Cited by 148
Storb, R. F., Deeg, H. J., Fisher, L. D., Appelbaum, F. R., Buckner, C. D., Bensinger, W., Clift, R., Doney, K., Irlé, C., & McGuffin, R. W. (1988) · Blood · doi:10.1182/blood.v71.2.293.293 · Cited by 147
Schmaltz, C., Alpdoğan, Ö., Muriglan, S. J., Kappel, B. J., Rotolo, J. A., Ricchetti, E. T., Greenberg, A. S., Willis, L. M., Murphy, G. F., Crawford, J. M., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2109 · Cited by 133
Cooke, K. R., & Yanik, G. A. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704629 · Cited by 119
Risk assessment in haematopoietic stem cell transplantation: Histocompatibility
Petersdorf, E. W. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2006.09.001 · Cited by 74
Wasem, C., Frutschi, C., Arnold, D., Vallan, C., Lin, T., Green, D. R., Mueller, C., & Brunner, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2936 · Cited by 40
Cited by
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.015 · Cited by 1,392
The microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200
Risk factors for acute GVHD and survival after hematopoietic cell transplantation
Jagasia, M., Arora, M., Flowers, M. E. D., Chao, N. J., McCarthy, P. L., Cutler, C. S., Urbano-Ispizua, A., Pavletic, S. Z., Haagenson, M. D., Zhang, M.-J., et al. (2012) · Blood · doi:10.1182/blood-2011-06-364265 · Cited by 707
Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation
Ogonek, J., Kralj Juric, M., Ghimire, S., Varanasi, P. R., Holler, E., Greinix, H., & Weissinger, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00507 · Cited by 458
Mouse models of graft-versus-host disease: advances and limitations
Schroeder, M. A., & DiPersio, J. F. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.006668 · Cited by 291
Metadata
- Authors
- Jacobsohn, D. A., & Vogelsang, G. B.
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2007-09-04
- Volume
- 2
- Issue
- 1
- Pages
- 35-35
- ISSN
- 1750-1172 (ISSN-L)
- OpenAlex
- W2117697495
- Cited by
- 299
- References
- 37
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.